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Elective orthopaedic surgery in patients with inflammatory 
arthropathies
1. Introduction and background 
Inflammatory arthropathy is an umbrella term for rheumatic diseases which causes 
inflammation of the joints, with joint destruction as one of the most serious consequences. 
Early systemic pharmacological treatment is the main and first choice of therapy, but when 
pharmacological treatment no longer provides adequate disease control, orthopaedic surgery 
is an option. The main goals of surgical interventions in  inflammatory arthropathies are pain 
relief and preserved or improved function (1).
During the past decades, modern surgical care has improved patients´ quality and length of 
life. However, formal and comparative assessment of procedures have been given minor 
attention, and only scant attention has been paid to patient and societal inconvenience or costs 
related to surgical interventions (2;3). Procedure-oriented evaluation has historically been the 
most common way of evaluating different surgical procedures, e.g. with revision of a 
prosthesis as the endpoint (4), but patient-oriented evaluations of pain and function are also 
important for assessing the impact of different surgical procedures and for evaluating whether 
treatment goals have been achieved (5).  Functional impairment, pain, and the subsequent loss 
of quality of life and work ability are the main considerations for surgical treatment (6). A 
study of patients with RA reported that pain is the factor most patients would like to see 
improved (7), and it is known that complications of different surgical procedures may have 
serious impact on patients’ quality of life.  Therefore, when evaluating results of surgery, 
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patient-reported measures are needed to capture a wide range of relevant and important 
aspects and domains of health and functioning
The potential chronic and fluctuating  course of the inflammatory arthropathies is a challenge 
with regard to decision-making and evaluation of effects of specific surgical procedures (5). 
Additionally, many patients with inflammatory arthropathies also have multiple joint 
involvements and suffer from co-morbidities. Due to the complex, chronic and progressive 
nature of the disease, thorough monitoring of patients is important, in order to make 
reasonable clinical decisions at the right time and in right order. For patients in need of long-
term care, a treatment plan should be established, based on information from patient-reported 
measures of symptoms, function and disease impact, patient priorities and clinical 
considerations.
Recent studies have demonstrated declining use of orthopaedic surgical treatment in patients 
with inflammatory arthropathies, as a result of the new and more aggressive medical 
treatment and the possibility of a milder disease (8-12). However, data registers of patients 
with total joint replacements include a large proportion of patients with inflammatory 
arthropathies, with cases ranging from 3-6 % of the total hip arthroplasty patients to more 
than 90% of patients receiving hand, elbow and ankle replacements (4;13-19). Further, 
several studies have shown that some patients do not respond to, or tolerate the new 
pharmacological treatment, and that progression of radiological damage may occur despite 
clinical remission (20-22). The importance of early diagnosis and treatment is generally 
accepted and delayed treatment will increase the risk of irreversible damage (23). However, 
despite the new era of modern biological medication, elective orthopaedic surgery will still be 
an important and necessary treatment alternative for patients with inflammatory arthropathies.
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The increasing success rate of total replacement surgery has resulted in a shift towards 
surgical interventions in younger populations (4;24). There has been a trend towards a more 
aggressive  rehabilitation phase, with earlier mobilisation and shorter hospital stay, indicating 
that  surgical interventions will influence patients’ health and daily life to a lesser degree than 
earlier (25). When evaluating surgical interventions also socio-economic evaluation is of 
importance, e.g. considering the cost-effectiveness of the different procedures (5). Patient-
reported outcome measures (PROMs) can provide information on the results after surgical 
interventions. Some of these measures may be used for calculation of gained quality adjusted 
life years (QALYs), based on the length of life and the quality of the life years. QALYs are 
frequently used to elicit patients’ preferences for health states, and the cost-effectiveness of an 
intervention can be evaluated by relating the costs to the changes in QALYs. When 
considering different treatment options available for the patients, cost analyses and QALYs 
are important in priority discussions and clinical decision-making.   
1.1 Diseases 
1.1.1. Inflammatory arthropathies 
There are three main categories of rheumatic diseases: inflammatory conditions (arthritic 
diseases, systemic connective tissue diseases etc), degenerative arthropathies (osteoarthritis) 
and soft tissue rheumatism (fibromyalgia). In this thesis, only patients with inflammatory 
arthropathies were included. Rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile 
idiopathic arthritis (JIA) and ankylosing spondylitis (AS) are the most frequent inflammatory 
joint diseases. The majority of the patients in the current studies had RA.
1.1.2 Rheumatoid arthritis 
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RA is a chronic systemic autoimmune inflammatory disease and the most frequent disorder 
affecting diarthrodial joints. The most common mode of onset is symmetric involvement of  
the small joints of the hands and the feet, but also larger weight-bearing and unilateral joints 
can be involved (26).
RA affects all ethnic groups throughout the world (26). The prevalence is estimated to be 
about 0.5-1.0 % among Caucasians (27;28) and the total annual incidence rate is about 25-
50/100 000. The onset of disease peaks at about 60 years of age (29;30) and females are 2.5 
times more likely to be affected than males (29;31). 
 Extra-articular manifestations can be seen in almost 50 % of all RA patients and consist of 
arteriosclerosis, pericarditis, pleuritis, major cutaneous vasculitis, Felty´s syndrome, 
neuropathy, anemia, opthalmological manifestations, glomerulonephritis and other types of 
vasculitis (32). Systemic symptoms may also occur, such as myalgia, fatigue, malaise, 
stiffness and fever. 
Patients with RA suffer from pain and reduced physical function, caused by both 
inflammation and structural damage (33;34) as well as impairment of other dimensions of 
quality of life (29). The working ability is reduced among patients with RA (35;36) which is 
an important socio-medical impact because of the significant financial and psychosocial 
losses for the patients (37). The rheumatic diseases are the single most costly group of 
disorders, measured in terms of hospital costs, medication costs and costs of lost days at work 
(38). In addition, the disease imposes a considerable economic burden on the patients (39;40). 
RA is diagnosed according to a set of criteria. The American College of Rheumatology 
(ACR) 1987 revised criteria for the classification of RA is the most widely used (41). RA is 
defined by the presence of at least 4 of the 7 items listed in Table 1. Antibodies to cyclic 
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citrullinated peptides (anti-CCP) are widely used for RA diagnosis, but are not included in the 
1987 ACR criteria for RA classification. Studies have shown that cyclic citrullinated peptides 
(CCP) improved the sensitivity of the ACR criteria most for patients with early symptoms and 
could be used for the classification of subjects of RA in the clinical studies (42;43).  New 
criteria focusing on early diagnosis will be published in the near future.  
Table 1 
1987 Criteria for the Classification of Acute Arthritis of Rheumatoid Arthritis 
Criterion Definition 
1. Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour before 
maximal improvement  
2. Arthritis of 3 or more joint areas At least 3 joint areas simultaneously have had soft tissue swelling or 
fluid (not bony overgrowth alone) observed by a physician. The 14 
possible areas are right or left PIP, MCP, wrist, elbow, knee, ankle, and 
MTP joints  
3. Arthritis of hand joints At least 1 area swollen (as defined above) in a wrist, MCP, or PIP joint  
4. Symmetric arthritis Simultaneous involvement of the same joint areas (as defined in 2) on 
both sides fo the body (bilateral involvement of PIPs, MCPs, or MTPs 
is acceptable without absolute symmetry)  
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or extensor surfaces, or 
in juxtaarticular regions, observed by a physician  
6. Serum rheumatoid factor Demonstration of abnormal amounts of serum rheumatoid factor by any 
method for which the result has been positive in <5% of normal control 
subjects
7. Radiographic changes Radiographic changes typical of rheumatoid arthritis on posteroanterior 
hand and wrist radiographs, which must include erosions or unequivocal 
bony decalcification localized in or most marked adjacent to the 
involved joints (osteoarthritis changes alone do not qualify)  
Criteria 1 through 4 must have been present for at least 6 weeks.  
The aetiology is largely unknown, but many factors contribute to the risk of developing RA, 
such as genetic factors, including human leukocyte antigen (HLA) shared epitope, hormonal 
factors, and environmental exposures such as tobacco smoking or infectious agents (44). 
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The primary target organ in RA is the synovial membrane. The normal synovium consists of 
an intimal lining layer, only one to tree cell levels thick. In RA changes include increased 
cellularity, increased vascularity, and infiltration with immune inflammatory cells which lead 
to a marked increase in tissue volume (45). Autoantibodies in RA include rheumatoid factor 
and anti CCP. Importance of humoral immunity is demonstrated by the efficacy of anti-B 
lymphocyte treatment strategies. T cells are involved in RA pathogenesis due to their 
presence in the synovium, association with HLA, presence of T-cell cytokines, and efficacy of 
anti-T lymphocyte treatment strategies. Cytokines are critical to RA pathogenesis and an 
imbalance between pro- and anti-inflammatory cytokine activities favours the induction of 
autoimmunity, chronic inflammation and thereby joint damage (46).  Mechanisms that result 
in destruction of cartilage and bone lead to joint deformities and disability (26;47). There is a 
relation between long standing inflammation, pathology of RA, disability, radiographic 
progression and joint damage (48). The proinflammatory cytokines tumour necrosis factor 
alpha (TNF-alpha), interleukin 1 (IL-1) and interleukin 6 (IL-6) have proved to be important 
targets for treatments.  
1.1.3 Ankylosing spondylitis 
Ankylosing spondylitis (AS) is the major subtype among the spondyloarthritides (SpA). The 
main characteristics of AS are chronic inflammation of the sacroiliac joints, spine and 
entheses. Some patients also have peripheral arthritis and also lesions from other organs, e.g. 
iridocyclitis, bowel disease and heart involvement (26).  
AS affects about 0.1- 2 % across different populations, most populations near the lower end 
of the range, but varies across ethnic groups and is correlated to the prevalence of human 
leukocyte antigen (HLA-B27). AS usually presents in young adulthood with a male: female 
ratio of approximately 2-3:1 (28;49;50).  
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The 1984 modified New York criteria is most widely used for the classification of AS (51). 
The diagnosis of AS is defined by the presence of criteria 4 or 5 and at least one of the clinical 
criterion 1-3 (Table 2). The modified New York criteria is useful in established disease, but is 
less applicable in patients with early disease. As the presence of x-ray confirmed sacroiliitis is 
essential for the diagnosis of AS, there is currently a delay between the first symptoms and 
the establishment of diagnosis of more than 5 years. However, chronic radiological changes 
are the consequence of inflammation and not the inflammation itself, and MRI may therefore 
contribute to confirm the diagnosis earlier. On this background, new classification criteria for 
axial SpA has been developed (52).
Table 2 Modified New York criteria for AS 
1. Low back pain for at least three months duration improved by exercise and some 
relived by rest 
2. Limitation of lumbar spine motion in sagital and frontal planes 
3. Chest expansion decreased relative to normal values for age and sex 
4. Unilateral sacroiliitis grade 3-4 
5. Bilateral sacroiliitis grade 2-3 
AS is largely determined by genetics and associated to HLA-B27 (53). About 90-95% of all 
patients with AS are HLA-B27 positive as compared to 7-8% of the general population, and 
the risk of developing AS is about 5% in HLA-B27 positive individuals. However there are 
other genetic markers than HLA-B27 which are also associated with AS (54-57)}. No 
environmental triggers have been identified in AS, but several studies support the hypothesis 
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that bacterial antigens, especially from the gut flora, play a central role in AS pathogenesis 
(58). Several studies indicate that CIA (Chlamydia induced reactive arthritis) and 
enterobacteria induced reactive arthritis may develop into AS. In arthritis induced by 
chlamydial species, organisms are viable and metabolically active in the synovium (59). 65-
85 % of patients with reactive arthritis classified as a type of seronegative 
spondyloarthropathy are HLA-B27 positive (60). The pathology in AS is characterised by 
bony formation with fusion of joints and intervertebral spaces (61). The disease may have a 
substantial impact on physical function, health related quality of life and work disability (62). 
The only known predictor of radiographic progression is structural damage on radiographs at 
baseline (63). 
1.1.4 Psoriatic arthritis 
PsA has been defined as an inflammatory arthritis associated with psoriasis. Radiographic 
damage has been reported to develop in near half of the patients within 2 years after disease 
onset (64). There are multiple clinical subsets of PsA reflecting variable clinical patterns 
including: distal joint disease, arthritis mutilans, oligoarthritis (less than or equal to four 
joints), RA-like polyarthritis and spondylitis (26).  
PsA occurs in approximately 25% of patients with psoriasis leading to prevalence in the 
population of 0.3% to 1%, mean age of disease onset is 40-50 years (65). The genders are 
equally represented. 
The Classification of Psoriatic Arthritis group (CASPAR) developed classification criteria for 
PsA in 2006 (Table 3). These CASPAR criteria for classification of PsA is 99% specific and 
92% sensitive for PsA (66).
Table 3 CASPAR criteria 
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1. Evidence of psoriasis (one of a, b, c)    a. current psoriasis  
                                                                    b. personal history of psoriasis  
                                                                    c. family history of psoriasis 
      2. Psoriatic nail dystrophy 
      3. A negative test for rheumatoid factor 
      4. Dactylitis (one of a, b)                           a. current                                                                                    
                                                                         b. history 
5. Radiological evidence of juxta-articular new bone formation 
PsA is triggered by a complex interaction between genetic and environmental factors.  
Patients with PsA are usually seronegative for RF. Various susceptibility genes to PsA have 
been identified. HLA-B27 is strongly associated with axial disease, whereas HLA-B38 and 
HLA-B39 are of more importance in peripheral disease (67). The environmental factors 
include trauma and infection (26). PsA histopathology differs from RA with the most striking 
difference in the characteristics of the synovial vasculature. Cellular immunity and cytokines, 
including TNF-alpha, are important mediators of PsA. Osteoclasts are important mediators of 
dysregulated bone remodelling in PsA. The burden of disease in PsA has been shown to be 
comparable with RA and AS (68;69). 
1.1.5 Juvenile idiopathic arthritis 
JIA is an umbrella term referring to a group of disorders that has in common chronic arthritis 
with onset during childhood, and is also one of the more common chronic childhood illnesses 
(26). 5-10% of those with JIA have a disease that resembles adult-onset RA much more than 
other types of JIA.
The prevalence of JIA is estimated to be 57-220 per 100 000 children younger than 16 years 
and about half the JIA patients have active disease that persists to adulthood (70;71).
JIA is an inflammatory disease with variations in genes within the inflammation networks that 
predispose the patients to disease. T-cell and cytokine profiles vary according to the JIA 
subtype and gene variations in the HLA region of chromosome 6 are associated with different 
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subtypes of JIA, except systemic onset JIA. In the current studies, only patients above 16 
years with persistent and symptomatic JIA in need of treatment were included.  
1.1.6 Other arthritides 
Some patients with other arthritides than those mentioned above were also included in this 
project. These patients had an arthritic disease which could not be classified according to one 
of the above mentioned criteria, e.g. undifferentiated arthritis. Patients with osteoarthritis 
were not included. 
1.2 Treatment of patients with inflammatory arthropathies 
The overall treatment goal for patients with inflammatory arthropathies is to reduce pain, 
minimize loss of function, preserve health-related quality of life (HRQoL) and prevent bone 
damage  (72). HRQoL represents the patient's evaluation of the impact of a health condition 
and its treatment on daily life. Optimal treatment includes both pharmacologic and non-
pharmacologic interventions such as surgical treatment, exercise, physiotherapy and patient 
education, as emphasized in the ACR and EULAR recommendations (73;74). 
1.2.1 Pharmacological treatment  
Early diagnosis and intervention are important since disability and damage increase rapidly 
during the first year of the disease (75). During the last years, there has been a tremendous 
increase in pharmacological treatments available for patients with inflammatory arthropathies. 
The use of expensive medication have expanded (76;77), but patient’s response to therapy has 
been shown to vary considerably (20-22;78). Pharmacological interventions for patients with 
inflammatory arthropathies consist of symptom-modifying and disease-modifying drugs 
(Table 4).
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Table 4 Main pharmaceutical interventions in inflammatory arthropathies
Classification Types 
Analgesics Paracetamol 
Codeine 
Tramadol 
Opioids 
Non-steroidal antiinflammatory 
drug (NSAIDs) 
Non-selective and COX2 selective 
Corticosteroids Local and systemic 
Conventional Disease-Modifying 
Antirheumatic Drugs (DMARDs) 
Methotrexate 
Sulfasalazine
Leflunomide 
Gold 
Antimalarial drugs 
Biological drugs (cytokine 
inhibitors) 
Adalimumab  
Etanercept 
Infliximab 
Golimumab  
Certolizumab 
Anakinra 
Tocilizumab 
Biological drugs (B and T cell 
targeted therapies) 
Rituximab 
Abatacept 
1.2.2 Surgical treatment  
Joint destruction is one of the most important consequences of inflammatory arthropathies 
and orthopaedic surgery is a treatment alternative expected to preserve or improve joint 
function and also to provide pain relief  (1;79). Once it has been established that a patient’s 
symptoms in a specific joint are related primarily to underlying structural damage, one should 
assume that the lesion is fundamentally irreversible and that orthopaedic surgery is the major 
therapeutic option (79). Patients with multiple joint involvements may need multiple surgical 
procedures over time, and it is therefore important to make a treatment plan. A thorough 
monitoring and a treatment plan will also contribute to good timing of surgical interventions, 
before joint destruction is too severe. Although there is available treatment for patients also 
with total destructed joints, it is more beneficial to maintain than to regain joint function 
(79;80). Distortion of the joint anatomy with accompanying soft tissue problems including 
tendon ruptures and osteoporosis, are factors that limit the choice of surgical procedures and 
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may have a negative impact on the results of surgical treatment. Timely referral for surgery is 
therefore important, and several studies underline that the pre-operative status is highly 
correlated with the post-operative gain in function and pain (5;61;80-85).
A number of different surgical treatment options are available for patients with inflammatory 
arthropathies. Orthopaedic surgery for this patient group is mainly elective treatment, with a 
few exceptions: instability of the cervical spine with resultant myelopathy and neurologic 
symptoms, rupture of the ulnar extensor tendons at the wrist and removal of the prosthesis 
from an infected joint (86).
The most common procedures are listed in Table 5. Procedures not performed at 
Diakonhjemmet Hospital are not mentioned or included in the papers (e.g. spine surgery). The 
different surgical procedures can be categorized according to location (upper and lower limb 
or specific joints) or according to the different procedures like replacement and non- 
replacement surgery. Further, differentiation of surgical procedures may also include surgery 
involving joints or soft-tissue.
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Table 5
Elective surgical procedures available for patients with inflammatory arthropathies 
Joint 
Replacement surgery (types of 
prosthesis*) 
Non replacement surgery (different types 
of surgery) 
Shoulder Total replacement  
Cement / cementless fixation 
Normal / reversed 
Arthroscopy / synovectomy 
Hemi prosthesis 
Cement / cementless fixation 
Surface / with stem 
Bi / unipolar 
Subacromial bursectomy 
Subacromial resection 
Elbow Cement/cementless fixation 
Non constrained (sloopyhinge)/ 
Semi-constrained prosthesis 
Arthroscopy / synovectomy 
Open synovectomy  
Resection of noduli/ bursa olecrani 
Nerve decompression 
Hand/fingers Cementless wrist total arthroplasty Arthrodesis  
Silicone prosthesis for the MCP joints  
One component 
Open synovectomy 
Two component prosthesis for the finger 
joints 
Arthroscopy / synovectomy 
Surgery on ligaments and tendons 
Resection of noduli 
Nerve decompression (Carpal tunnel 
syndrome (CTS)) 
Hip Total hip arthroplasty 
Cement/cementless fixation 
Arthroscopy / synovectomy 
Hemiprosthesis 
Cement / cementless fixation 
Knee Total knee arthroplasty 
Cement/cementless fixation 
With or without the patella component 
Arthroscopy / synovectomy 
Ankle / foot Uncemented 3 component ankle 
replacement 
Arthrodesis   
Silicone prosthesis for the first MTP Surgery on ligaments and tendons 
Resection of nodulus 
Surgery on ligaments and tendons 
Forefoot resection arthroplasty 
(Tillmann) 
Other minor surgery 
1.2.3 Non-pharmacological, non-surgical treatment 
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Over the last decades, rehabilitation, (including patient education, physiotherapy and 
exercise) is increasingly reported to have an important impact on patients’ ability to manage 
disability and to improve physical functioning and self-management (87-89) . Because of fear 
for aggravation of disease activity and symptoms, people with inflammatory arthropathies 
have earlier been advised to limit the amount of physical activity and to protect their joints 
when exercising physically. However, current evidence supports that people with joint 
diseases should be encouraged to exercise in order to maintain or improve physical and 
mental health and reduce the risk of co-morbidities (87-91). Thus, rehabilitation programs 
based on updated knowledge have the potential of enhancing the beneficial effects of surgical 
interventions for patients with inflammatory joint diseases (73;87;91).
1.3 Measures of disease status 
Measures of disease status in inflammatory arthropathies can be categorised into three main 
dimensions (figure 1):  
 markers of inflammation measured by laboratory tests
 alteration in structural damage illustrated by abnormalities on x-rays  
 functional consequences of the disease measured by patient-reported outcome 
measures (PROMs)  
Laboratory markers of disease activity or x-rays were not included in this project. However, 
several  studies report that disease activity and radiographic damage are strongly related both 
to physical functioning and pain (34;48;92-95). In chronic diseases quantifiable and 
standardized information concerning health status, pain and function are of special importance 
since such information is critical in the documentation of patient outcomes and results of care. 
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Such information can be collected easily and effectively from questionnaires completed by 
the patient (96).
‘Patient-reported outcome measure’ (PROM) is a short-hand term referring to the array of 
questionnaires, interview schedules and other related methods of assessing health, illness and 
benefits of health care interventions from the patient’s perspective. PROM, addressing 
constructs such as health-related quality of life, subjective health status and functional status, 
are increasingly used as primary or secondary end-points in clinical trials (97). In PROMs, 
attention is given to patients´ preferences and wishes, thus providing a feasible and 
appropriate method for addressing the concerns of patients both in the context of clinical trials 
and in clinical care (97). The PROMs used in this project are thoroughly described in section 
3 (Material and Methods) and discussed further in the section 5 (Discussion).
2. General aim and specific research questions 
2.1 General aim 
The general aim of this thesis was to explore longitudinal outcomes and other relevant aspects 
related to elective orthopaedic surgical procedures in patients with inflammatory 
arthropathies, with a special focus on potential differences in upper and lower extremities.  
2.2 Specific research questions 
1. What is the overall magnitude of change in lower and upper limb physical function over a 
10-year period in patients with RA? 
2. Are there differences in disease characteristics in patients referred for hand surgery 
compared to those referred for foot surgery? 
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3. Clinical outcomes after orthopaedic surgical procedures in patients with inflammatory:  
- how are the longitudinal changes in pain, physical function and health related
quality of life? 
- how are the longitudinal changes in clinical outcomes for replacement surgery 
compared to non-replacement surgery? 
- how are the longitudinal changes in clinical outcomes for surgical procedures in 
the upper limbs compared to the lower limbs?  
4. Cost-outcome descriptions of elective orthopaedic surgical procedures in patients with 
inflammatory arthropathies:  
- how are the over all costs per QALY gained of surgical interventions? 
- how are the costs per QALY gained after replacement surgery compared to the 
gain of non-replacement surgical interventions? 
3. Material and methods 
3.1 Study designs  
Papers I, III and IV have longitudinal observational study design, whereas Paper II is based 
on a cross sectional study design.
3.2 Data sources
Paper I is based on data from patients included in the Oslo Rheumatoid Arthritis Register 
(ORAR) supplemented with data collected from the patients’ hospital records. Outcome 
measures reported from the ORAR are measures of physical function and general health 
(MHAQ, AIMS2 and SF-36).  
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Papers II, III and IV include patients’ with confirmed inflammatory arthropathies 
consecutively admitted and assessed for surgical procedures 2005-2006. The patients 
responded to a booklet of questionnaires including AIMS2, HAQ, SF-36, EQ-5D and visual 
analogue scales (VAS) addressing patient global, fatigue, general pain and pain in actual joint 
(Table 6). Demographic data and information on medication were confirmed in the hospital 
records.  In addition, Paper IV also includes data from the hospital’s cost per patient 
accounting system (KOSPA) database (section 3.4.4). 
Table 6 Data sources and variables used in Paper I-IV 
PAPER Data source  Variables  
Paper I Data from the ORAR  
Hospital records  
Demographic and disease related variables, 
MHAQ, AIMS2, SF-36, 
RA-related surgical procedures 
Paper II Cross-sectional data from patients 
undergoing surgical procedures  
Data from the patients hospital records 
AIMS2, HAQ, SF36 
Demographic and disease related variables 
including sex, gender, disease duration and 
medication   
Paper III Longitudinal data from patients 
undergoing surgical procedures  
Hospital records 
Demographic variables, AIMS2, HAQ, SF-36, 
EQ-5D and visual analogue scales (VAS) 
addressing patient global, fatigue, general pain and 
pain in actual joint. 
Paper IV Longitudinal data for patients undergoing 
surgical procedures 
KOSPA database  
Hospital records 
 Demographic variables,  SF-36, EQ-5D  
Costs related to the hospital stay 
3.3  Study populations 
Patients from the ORAR (see description below) are included in Paper I. Paper II to IV are 
based on patients’ with confirmed inflammatory arthropathies who were admitted and 
assessed for surgical procedures at Diakonhjemmet Hospital 2005-2006.  
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3.3.1 The Oslo Rheumatoid Arthritis Register  
The ORAR was established during the years 1991 to 1994 (27;98), with the purpose of 
providing epidemiological data that is representative of the entire population in the county of 
Oslo, with a population of approximately 550 000 inhabitants (98). The number of enrolled 
individuals in 1994 was 1,552 patients (27). The diagnosis of RA, a residential address in 
Oslo and the age at disease onset more than 16 years, are the inclusion criteria (41). The 
register is continuously updated and the completeness of the register is estimated to be 85% of 
the total population of patients with RA in the geographic area of Oslo (27).
3.3.2 Patients undergoing surgical procedures 2005-2006 
Paper II to IV consists of patients’ with confirmed inflammatory arthropathies consecutively 
admitted and assessed for surgical procedures from February 2005 to May 2006. The database 
consists of 414 patients who underwent orthopaedic surgical treatment and responded to the 
surveys (replied both by mail and at hospitalisation) at baseline and at least one point of 
follow up. The distribution of diagnoses was as follows: RA (64.2%), JIA (3.9%), AS (5.1%), 
PsA (7.4%) and other arthritides (12.0%). Mean (SD) baseline age was 57.5 (13.1) years and 
76.7 % were female.  
In Paper II to IV, patients with osteoarthritis were not included.  Patients who underwent 
revision surgery, surgery because of fractures or secondary infections were also excluded, and 
each patient was only included once, even if they underwent multiple interventions during the 
inclusion period. The patients responded to questionnaires preoperatively and 3, 6, 9 and 12 
months after the surgical intervention. 
3.4  Assessments 
3.4.1 Demographic and disease related variables  
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Self-reported questionnaires and the hospital records were used to obtain information about 
demographic and disease related variables like gender, age, disease duration, medical 
treatment and surgical intervention. 
3.4.2 Patient-reported measures 
In this project, patient-reported outcomes were recorded by means of the following 
instruments:  
 Four visual analogue scales addressing patient global assessment of disease, fatigue, 
general pain and pain in the specific joint undergoing surgical intervention 
 Two standardised, disease specific instruments for measuring physical function: the 
HAQ (MHAQ) and the AIMS2 
 The generic health status instruments Short Form-36 and EQ-5D 
3.4.2.1   The Health Assessment Questionnaire and the Modified Health Assessment 
Questionnaire
The Modified Health Assessment Questionnaire (MHAQ) is an 8 item shortened version of 
the Health Assessment Questionnaire (HAQ) developed for patients with RA and 
osteoarthritis (92;99). HAQ and MHAQ focus on physical function. The HAQ includes 
questions assessing difficulty over the past week in 20 specific functions, grouped into 8 
categories: dressing and grooming, arising, eating, walking, personal hygiene, reaching, 
gripping, and other activities. Modification of the HAQ (MHAQ) was done by including only 
one item within each of the 8 categories. The responses to “are you able to do…” were scored 
0-3 in the HAQ (without any diffuculty = 0, unable to do = 3) and 1-4 (without any difficulty 
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= 1, unable to do = 4) in the MHAQ. The MHAQ has been shown to provide essentially the 
same information as the longer original HAQ, but the scores are generally lower (100).
3.4.2.2 The Arthritis Impact Measurement Scales 
The expanded version of the Arthritis Impact Measurement Scales (AIMS2) is a disease-
specific measure of physical, social, and emotional well-being designed as a measure of 
outcome in arthritis, and has been translated into many languages including Norwegian (101-
104). The first 57 items of AIMS2 are broken into 12 scales: mobility (five items), walking 
and bending (five items), hand and finger function (five), self-care tasks (four items), 
household tasks (four items), social activity (five items), support from family and friends (five 
items), arthritis pain (five items), work (four items), level of tension (five items) and mood 
(five items). The scales may be combined into a five-component model reflecting the physical 
dimension, affect, symptoms, social interaction and role. The score of each scale ranges from 
0-10 (10 represents worst health). AIMS2 was scored according to the AIMS2 user’s guide 
issued by the Boston University Arthritis Centre. 
3.4.2.3  The Short Form 36  
The Short Form 36 (SF-36) is a generic health status measure, not specific to any age, disease, 
or treatment group, and has been used in a variety of conditions including RA, 
musculoskeletal disorders and patients who have undergone replacement surgery(105;106). 
The SF-36 assesses eight areas of health as follows: limitations in physical activities caused 
by the disease, limitations in the social functioning of patients as a result of physical and/or 
emotional problems, limitations in the usual role functioning (work or other daily activities) 
as a result of emotional problems, limitations in the usual role functioning as a result of 
physical health problems, bodily pain, general mental health (feelings of well-being, 
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depression etc.), vitality (energy and fatigue), general health perceptions. Scores in the range 
0-100 are calculated for each of these different aspects of health, with low score indicating 
poor health status. The SF-36 has been compared to various disease specific instruments. In a 
study of RA patients, the physical functioning scale of the SF-36 did not seem to capture all 
aspects of physical health , but showed to be more sensitive than disease-specific measures 
for low levels of physical disability (106). 
3.4.2.4  Visual analogue scales
Visual analogue scales (VAS) are also included in Paper III. VAS is used to record the 
patients’ health status. The 4 different VAS included are as follows: pain, fatigue, general 
pain and pain in the actual joint. The score was recorded on a 100 mm scale and patients were 
asked to mark the score that best represented their pain or fatigue the last week.
3.4.3 Utility scores 
The term utility comes from the field of economics and refers to the total satisfaction from 
consuming a good or a service. In health science, utility is defined as a preference for a 
particular health status or outcome. Utilities can be transformed to quality adjusted life years
(QALYs), which is a common “metric” for outcomes, used for cost-utility analyses. Utility 
scores quantify health related quality of life along a criterion that typically ranges from 0 
(death) to 1 (full health). Utility scores can be negative, reflecting health states worse than 
death (107).  Different methodological approaches are used by health economists to determine 
weightings for utility scores or QALY analyses, e.g. standard gamble (SG), time to trade-off
(TTO), and rating scales (RS) (107-110). SG is a method of calculating utility values for 
health states in which participants are asked what percentage risk of death, if any, they would 
take in order to have the chance of a return to normal health (107). In the TTO method, 
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participants are asked if a treatment was available that could return them to good health, but 
would reduce the length of their life, how many of they remaining years would they be 
prepared to relinquish in return for normal health (107). In the RS method, the subjects are 
asked to locate their health state on a rating scale (e.g. 0-100) (110).
The utility scores (EQ-5D and SF-6D) are single index number instruments which have the 
advantage of showing the overall measure as a single number which might facilitate the 
understanding and comparison of  the scores. EQ-5D and SF-6D are utility scores reported in 
quality adjusted life years (QALYs)  (105;106;111;112). QALY is a measure used to elicit 
preferences for health states and is based on two factors:  the length of life and the quality of 
those life years. QALYs are frequently used in political- and priority discussions regarding 
health care. Health care have two major objectives: to keep people alive and to improve their 
health related quality of life and effectiveness of health care can be assessed in terms of 
changes in QALYs. Different HRQoL instruments, both generic and diseases specific 
instruments may be reported as QALYs (113;114). The utility scores were in Paper III used 
for evaluation of the longitudinal impact of surgical interventions and in Paper IV to calculate 
the cost per QALY after surgical procedures. 
.
3.4.3.1 SF-6D
The SF-6D is derived from the SF-36 and transformed to a utility score (scale 0-1, where 0 is 
equal to death and 1 is equal to perfect health). The eight dimensions of SF-36 are translated 
into 6 dimensions (physical function, role limitations, social function, pain, mental health and 
vitality) by means of an algorithm. The level of severity in each dimension is determined by 
responses of related items in SF-36 (115). The lowest achievable value with SF-6D for living 
patients is 0.29 (112). The SF-6D is based on SG as valuation technique.
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3.4.3.2 EQ-5D
The EQ-5D is a standardised instrument for the use as a measure of health outcome, designed 
for self-completion (116). The EQ-5D has a 3-level, 5 dimensional systems, including the 
following five dimensions: mobility, self care, usual activities, pain/discomfort and 
anxiety/depression. The patients are asked to indicate no, moderate or severe problems with 
each of the five dimensions (111;112;116). The scoring of the EQ-5D instrument is translated 
into a utility weight where 0 represents death and 1 perfect health (111;112;116). Also 
negative values can be achieved in living patients, indicating that living persons can have a 
health status worse than death (maximum -0.59). The EQ-5D is based on TTO and visual 
analogue scales as valuation techniques.
3.4.4 Costs
The costs for the hospital stay were estimated by use of data from the KOSPA database 
(Paper IV). The KOSPA is an iterative calculation model, which allocates hospital costs to the 
different patient activities based on the electronic patient activity register (Distributed 
Information and Patient system in Hospitals (DIPS)) and a set of cost allocation criteria. The 
KOSPA model was developed by Analysesenteret AS, Oslo (www.asl.no) and adapted at 
Diakonhjemmet Sykehus AS, Oslo and a number of other hospitals in Norway.  The KOSPA 
database system calculates the cost per patient during the hospital stay and may also calculate 
the costs per outpatient during day treatment in hospital. Some costs, such as use of imaging 
and operation resources (i.e. surgical materials and personnel time), are assigned directly to 
each patient. The ward costs, including nurses, physicians and physiotherapists time use, as 
well as pharmaceuticals and other utilities, are estimated as an average cost per day in the 
wards and are assigned to each patient according to their length of stay in the respective 
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wards. Overhead costs (excluding depreciation and cost of capital) are distributed according 
to a set of criteria (such as the number of employees, the number of beds in use etc.).  
The costs calculated for each patient in this study were the costs the first year after surgery, 
which were defined as all hospital related costs including preoperative examinations, stay in 
the hospital and all postoperative follow-up visits. 
3.4.5 Cost per QALY 
The cost per QALY measure is calculated by the utility score and the relevant costs. Costs per 
QALY is a standardised measure and may therefore be used for comparison between studies. 
Yet, the costs included in the stipulations are the relevant costs for the actual intervention or 
service, thus, for comparison and interpretation of results, the costs included must be 
thoroughly defined (117). This issue is further addressed in the Discussion-part. 
3.4.6 Economic model 
A modification of an economic model described by Faulkner et al was adopted in Paper IV to 
calculate the cost-effectiveness of the surgical interventions (118). The economic model was 
created to estimate costs concerning total hip arthroplasty (THA). The model calculates 
expected costs for several years and includes costs concerning implant and surgical 
intervention, various hospital costs, patients’ age at time of surgical intervention. In addition, 
for this study, we included the outpatient costs the first year concerning the surgical 
intervention, the possibility of re-revisions and adjustments for differences in mortality rates 
in RA compared to the general population.  
3.4.7 Surgical procedures
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In Paper I, the hospital records were used for recording the number and category of RA-
related surgical procedures for each patient, the surgical procedures were categorised in two 
main groups: surgical procedures involving upper or lower limbs. In Paper I, numbers of 
surgical procedures were used as a covariate in the statistical analyses.
In Paper II to IV all the patients included had undergone different surgical procedures and in 
Paper III and IV the different surgical procedures were also categorized into replacement and 
non-replacement procedures. 
The primary large joint replacements are referred to as replacement surgery in this project, 
whereas the total replacements in the small joints (MCP, PIP and MTP joints) were 
categorized as other surgical procedures. This categorising was performed in order to 
establish more homogenous groups according to the postoperative follow-up and 
rehabilitation program.  
3.5 Statistics  
The statistical analyses in this thesis were performed using the statistical package for the 
social sciences for Window software, versions 14-15 (SPSS, Chicago, IL, USA) (Paper I-IV).
Microsoft Office Excel 2003 was used for the probabilistic and subgroup analyses (Paper IV). 
P-values equal to or below 0.05 were considered to be statistically significant. A statistician 
was consulted about the statistical analyses. 
Descriptive statistics were presented as numerical values or percentages, median (interquartile 
range) or mean (standard deviations (SD)) and 95 % confidence intervals. Within group 
changes from baseline to follow-up examinations were analysed using paired t-test for 
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continuous variables and independent sample t-tests were used to compare longitudinal 
changes between groups. 
Analyses of covariance (ANCOVA) were applied to compute the 10 year changes in physical 
function with adjustments for age, sex, disease duration, and number of surgical procedures in 
Paper I. Cross-tables and chi-square tests were used to compare differences in the medication 
and the distribution of the diagnosis between the groups of patients in Paper II.
Uncertainty in the model parameters (survival of the arthroplasty, costs and utility changes) 
was assessed by means of probalistic analyses. Beta distributions were fitted to the estimated 
probabilities for survival of the arthroplasty, and gamma distributions were fitted for the 
estimates of in- and outpatient costs and utility changes. The parameter estimates were 
assessed by 25.000 simulations with the specified distributions. In the cost-outcome analyses, 
all mean costs and QALYs for the different types of surgery were estimated on the basis of 
Monte Carlo simulation (119). Monte Carlo simulation is a problem-solving technique used to 
approximate the probability of certain outcomes by running multiple trial runs, called 
simulations, using random variables.  
A widely used strategy for dealing with missing longitudinal data is the last observational 
carried forward (LOCF) method. LOCF is a simple longitudinal imputation method, were the 
missing data point is given the same value as the last observed value (120). LOCF was used to 
replace missing values during follow-up in Paper II – IV.
The standardized response mean (SRM) reflects the magnitude of an improvement (or 
deterioration) and was computed as the change from baseline to the 2 months follow-up, 
30
divided by the standard deviation of this change score. The magnitude of the SRMs were 
interpreted in terms of the thresholds introduced by Cohen for effect sizes: “trivial” (<0.20), 
“small” (>0.20<0.50), “moderate”(>0.50<0.80 or “large” (>0.80) (121). SRMs are 
comparable across the different instruments, independent of the instrument scales.   
3.6 Legal and ethical aspects 
All studies were conducted according to the principles of the Declaration of Helsinki. Patients 
gave written informed consent before participation. The studies were approved by the 
Regional Committee for Medical Research Ethics. The storage data was approved by the Data 
Inspectorate. 
4. Summary of results 
4.1 Paper I 
Patients with Rheumatoid Arthritis report greater physical functional deterioration in lower 
limbs compared to upper limb over 10 years. 
The purpose of this study was to examine to overall magnitude of change in self-reported 
physical function over a 10 year period in RA patients, and to compare 10 year changes 
between the lower and upper limbs concerning physical function.  
A total of 414 patients collected from patients in the ORAR register with mean age 55 years 
were included in these analyses. The mean disease duration was 11.6 years at baseline. 56% 
of the patients underwent surgical intervention because of their RA during the 10 year follow- 
up period. The change in overall physical function was measured by the SF-36, the MHAQ 
and the AIMS2. Changes in physical function in upper and lower limb were measured by 
AIMS2 physical and MHAQ. The analyses were adjusted for age, sex, duration of disease, 
and number of surgical procedures in the lower and upper limbs. 
31
The overall physical function deteriorated in RA patients over a 10 year period. The patients 
reported that lower limb function deteriorated more than upper limb function over a 10-year 
period, and the results were consistent after adjustment for number of surgical procedures.
Our results indicated a greater deterioration in physical function in the lower than upper limb 
over a 10 year period in patients with established RA. 
4.2 Paper II 
Patients with inflammatory arthropathies undergo feet surgery later in the disease course 
than hand surgery
The main objective of this study was to compare disease duration, patient-reported health 
status measures and use of medication in patients with inflammatory arthropathies referred for 
hand or foot surgery. 
During the study period, 116 patients with inflammatory arthropathies undergoing hand and 
foot surgery were included. A comprehensive booklet of disease related and generic 
questionnaires were filled in by the patients at baseline and data on disease duration, surgical 
treatment and medication were collected from the hospital records. 
Baseline values for the patient-reported health status measures were mainly similar for the 
patients undergoing surgical procedures in the upper and lower limb. However, patients 
undergoing surgical procedures in the foot had significantly longer disease duration than 
patients undergoing surgical procedures in the hand (19 vs. 13 years, p= 0.04). Further, we 
found that patients undergoing foot surgery were more frequently on potent medication at the 
time of surgery compared to patients undergoing hand surgery (71 vs. 50 %, p=0.02). 
Our findings supported that foot affliction in inflammatory arthropathies may be 
underestimated. 
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4.3 Paper III
Orthopaedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on 
pain, physical function and health related quality of life. 
In this paper our main objective was to examine the effectiveness of orthopaedic surgery, with 
regard to longitudinal changes in pain, physical function and HRQoL. We also wanted to 
explore the differences in effectiveness between replacement and non-replacement surgical 
interventions, and between surgical procedures in upper and lower limb.  
255 patients with inflammatory arthropathies, mean age 57.5 years responded to mail surveys 
before surgery and 3, 6, 9, 12 months after surgery. SRMs were calculated to estimate the 
magnitude of improvement and facilitate comparison between the different measurements 
with various numerical scales.    
Significant improvements were seen for most of the dimensions of health. Yet, the largest 
improvement was seen for the pain scores, and especially for pain in the actual joint. Similar 
improvement was seen after surgery in the upper and lower limbs, but patients undergoing 
replacement surgery experienced larger improvement than patients undergoing other surgical 
procedures.
Our results indicated that surgical procedures in patients with inflammatory arthropathies 
have major positive impact on pain in actual joint, but less improvement in other dimensions 
of health. Health benefits after replacement surgery were larger than health benefits after 
other surgical procedures.
4.4 Paper IV 
Cost-effective analyses of elective orthopaedic surgical procedures in patients with 
inflammatory arthropathies
33
The main aim of this study was to examine the cost per QALY gained of surgical 
interventions in patients with inflammatory arthropathies and, secondly, we assessed the costs 
per QALY gained for replacement compared to non-replacement surgery. 
In total 248 patients with inflammatory arthropathies undergoing orthopaedic surgical 
treatment were included. These patients responded to mail surveys at baseline and 3, 6, 9 and 
12 months after surgical intervention. The comprehensive booklet of questionnaires also 
included the utility scores EQ-5D and SF-6D, and the health benefit from surgery was 
subsequently translated into QALYs. 
The KOSPA system was used to derive the direct treatment costs for each patient the first 
year.
Significant improvements in utility scores were found at 12 months follow-up (0.10 with EQ-
5D and 0.03 with SF-6D (p<0.05)). We found that the estimated 10-year cost per QALYs 
gained were €5,000 for hip replacement surgery (€18,600 using SF-6D) and €10,500 (SF-6D 
€48,500) for all replacement procedures. The five-year cost per QALY was €17,800 for non-
replacement surgical procedures measured by EQ-5D (SF-6D: €67,500). 
In conclusion, we found that elective orthopaedic surgery in patients with inflammatory 
arthropathies was cost-effective when measured with EQ-5D. Some procedures were also 
cost-effective when SF-6D was used in the economic evaluations. We confirmed, as shown in 
previous studies, that hip replacement surgery was the most cost-effective procedure, 
irrespective of analysis method. 
5. Discussion
The general discussion of this thesis will focus on two main issues: First, the methodological
aspects, in terms of design, data collection, outcome measures and statistical procedures are 
discussed, and secondly, the main results and their clinical implications. 
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5.1 Methodological aspects 
5.1.1 Study samples 
In epidemiological, observational studies, the participants are selected from a larger group of 
potential subjects, and the validity of the extrapolation of results depends on the 
representativeness of the sample included (122). The identification and inclusion of non-
random samples impact the validity of the study, and a high level of representativity is needed 
for generalisation of the results to the entire underlying population.
Different types of selection bias may influence epidemiological studies, like for example left 
and right censorship (123). Left censorship in longitudinal studies refers to the potential bias 
introduced when the most severely affected patients are excluded from the recruitment, for 
example due to the effort of filling in the questionnaires or not being able to complete the 
intervention of interest. On the other hand, bias related to potential loss of follow-up is 
described as right censorship. The results of the current studies may to a certain degree be 
influenced of both left and right censorship, and this will be discussed below.
 . 
5.1.1.1 The Oslo Rheumatoid Arthitis Register 
Paper I includes patients from the ORAR which is annually updated with new and deceased 
cases, and was estimated in 1994 to have a completeness of 85 % (27;124). The assumption is 
that results from ORAR are representative of the underlying population of RA patients in 
Oslo. A population survey in 1994 supported this hypothesis (27;125), which is important for 
the external validity of results from ORAR. More recent data collections may be influenced 
by factors that have interfered with the completeness of the register, for example new 
characteristics and organisation of the health care. There has been an alteration in the 
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functional assignment between the rheumatology centres in Oslo, the patients have recently 
got the opportunity of 'free choice' of hospital, and  the number of patients treated in private 
practice in Oslo may have increased. However, the number of patients in ORAR has been 
quite stable since the establishment in 1994, with a numeric increase over the years, which 
approximately mirror the increased population in Oslo. The differences between the 
respondents and non-respondents have been estimated and indicated only minor differences in 
age, disease duration and percentage with positive rheumatoid factor (11). 
5.1.1.2  Patients undergoing surgical procedures 
Paper II, III and IV include patients with confirmed inflammatory arthropathies consecutively 
admitted and assessed for surgical procedures between February 2005 and May 2006 at 
Diakonhjemmet Hospital in Oslo. The database included 361 patients with inflammatory 
arthropathies who were asked to participate in this study at the time they were inducted for the 
surgical intervention. The patients who responded positively and completed the preoperative 
questionnaire were included in the database. Patients who fulfilled the planned surgical 
intervention were included in the current analyses (70 %). The "non-participants" (30%) were 
excluded for three reasons:  
- the planned surgical procedure was not performed for reasons due to the patients 
health
- the patient underwent a revision surgery
- the follow-up questionnaires were not completed  
The response rate in this study was similar to other surveys based on ORAR (11;125). 
However, examples of left censorship bias may be represented, as some of the most 
severely diseased patients may have been excluded due to the reasons mentioned above. 
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Further, right censorship bias may also have occurred, as patients who underwent 
replacement surgeries were more likely to have missing values in their follow-up data 
than patients who underwent non-replacement surgery. Likewise, the oldest patients also 
had a slightly higher percentage of missing values than the younger patients, whereas 
missing values were independent of gender and diagnosis. 
In Paper III and IV, the different surgical procedures were divided into main categories of 
surgical interventions, like replacement and non-replacement surgery. This approach gave 
the opportunity of estimating and analysing outcome after broader categories of surgical 
interventions.  The term replacement surgery refers to the primary large joint 
arthroplasties whereas total replacements in the small joints (MCP, PIP and MTP joints) 
were categorized together with other surgical procedures for analytic purposes. This 
categorisation was performed in order to establish more homogenous patient groups, 
based on the differences in extent and content of the postoperative rehabilitation program 
in patients undergoing large joint versus small joint arthroplasties and non-replacement 
procedures.
5.1.1.3  The KOSPA database 
The KOSPA database (described in section 3.4.5) is the hospital’s cost per patient accounting 
system which is an iterative calculation model. The hospital costs are allocated to the different 
parts of patients activities based on the electronic patients activity register and a set of cost 
allocation criteria. The costs included in the database are partly assigned each individual 
patient. Some of the costs are average costs and some are overhead costs distributed by an 
iteractive calculation model and numerous data are taken into account in these calculations, 
e.g. registration in the hospital records according to diagnoses, interventions and length of 
stay in hospital. Such factors are registered in the hospital records by different health 
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professionals which may create some inaccuracy in the data recorded for each patient. 
However, the fact that many of these data are controlled by other professionals compensate 
for some of the uncertainties.  
5.1.2 Study designs and data collection 
The designs and methods applied in this thesis have limitations and strengths which will be 
discussed below.
Paper I, III and IV are based on longitudinal study designs which involves data collection at 
more than one point of time and is appropriate for studying variables or phenomenon over 
time (126-128). Even if the randomised controlled trial (RCT) design is associated with the 
highest level of evidence, longitudinal observational studies can also provide important 
evidence of effectiveness because the patient population is closer to an unselected population 
and the follow-up is performed in a real life setting (129;130). The term effectiveness, as 
opposed to efficacy, refers to how well a treatment performs outside the context of an RCT.
Few RCTs or comparative observational studies examining effects of surgical interventions 
for patients with rheumatic diseases are available (131). A strength of the observational 
longitudinal design applied in this project, was that the study population probably reflects the 
'real-life' situation closer than populations in clinical trials with strict inclusion criteria. Thus, 
the results of such studies may have high external validity for clinical practice (126-128).
Paper II is based on a cross-sectional study design.  Cross-sectional designs involve collection 
of data at one point in time, and are especially appropriate for describing the status of a 
phenomenon or examining associations between phenomena at a fixed point in time. The 
main advantage of cross-sectional designs is that large amounts of data may be collected with 
moderate resources (132).
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5.1.3 Assessment 
5.1.3.1 Patient-reported outcome measures 
In chronic diseases, quantifiable and standardized information concerning health status, pain 
and function are of special importance since such information is critical in the documentation 
of patient outcomes and results of care. This information can be collected with high feasibility 
and effectively from questionnaires completed by the patient (96). Such PROMs are 
increasingly being recognised as important complements to information and knowledge 
obtained from clinical assessments (92-94).. 
Patient-reported data rely on the assumption that information given by the participants 
themselves is valid, reliable and responsive. This assumption has also been supported in 
recent studies (133;134). A study comparing patient-reported and physician-reported 
assessments concluded that improvements in signs and symptoms of active RA in RCTs 
appear to be best reflected by patient-reported measures. (133;135).  
Conclusively, PROMs have shown to provide information similar to many clinical measures 
and are at least as responsive. Further, PROMs also appear to be a cost effective and attractive 
approach for quantitative assessment and monitoring of health status of the individual patient 
(92) and should be included when results are reported in RA clinical trials.(136). 
Both generic and disease specific PROMs are used in this thesis. Generic health status 
instruments are designed to capture various aspects of health in any population irrespective of 
diseases or condition and may have the potential to highlight domains of disease 
consequences. Generic instruments can be used for comparisons between different patient 
groups and between patients and healthy controls. However, it may be questioned if the broad 
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scope of generic instruments adequately reflects health problems in populations with specific 
disorders, and the instruments may contain irrelevant items (137;138).  
Diseases-specific instruments are useful for assessing and monitoring disease related factors 
in patients with specific diseases or disorders, and are likely to address issues that are relevant 
to the respondents, thereby also with the potential of being more sensitive to change than 
generic instruments. Because of the different qualities of the instruments, they may provide 
complementary information.   
HRQoL represents the patient's evaluation of the impact of a health condition on daily life and 
has originated from two different approaches: health status and health value/preference/ utility 
assessment (139). In general, health status measures describe a person’s functioning in one or 
more domains (e.g. physical functioning or mental wellbeing), whereas utility measures 
assess the value or desirability of a state of health against an external metric. Utility measures 
are generic, direct or indirect measures that are summarized and expressed as a single number 
(140-142). Direct health utilities are usually ascertained via face-to face interviews, with 
computer assisted administration being the state of the art. Indirect health utilities use 
population assigned weight to calculate utility scores for particular health states from health 
scale instruments (143;144). The ease of administration of these indirect measures enables 
them to be used in national surveys, and they are commonly used as the source of quality of 
life weightings in economic evaluations. EQ-5D (111;116) and SF-6D (115) are examples of 
such indirect utility measures and single index number instruments. 
The advantage of the single number utility score compared to a profile instrument is the 
perspective of an “overall outcome”, which may be more easily understood and interpreted 
than the more complex profile indexes. On the other hand, a weakness with the single number 
index compared to the profile index is that no detailed information is provided regarding 
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which specific domains contribute to change in scores during clinical course or after 
interventions.  
A strength of this study is the comprehensive data collection, including utility scores, generic 
instruments and disease specific measures, thus capturing the same construct or domain by 
use of several different instruments (112). Consistent results across instruments support the 
robustness of the results. However, in Paper III, the large number of instruments may have 
represented a burden for the patients, since missing values occurred with a frequency of about 
one third at each point of follow-up.  
Further, a large number of tests may also increase the chance of finding statistically 
significant results just by chance (type I error).  Statistical adjustments of numerous tests may 
be used to reduce this problem, as for example the Bonferroni correction (122). However, 
since Paper III was considered to be an explorative study, such adjustments were not applied.   
In Paper IV, the two utility instruments EQ-5D and SF-6D were used to capture patients 
perceived health changes after surgical intervention. Due to the well known different profiles 
of these instruments with regard to floor and ceiling effects, the two instruments showed, as 
expected, different magnitude of improvement  (112;141). Consequently, more favourable 
cost per QALYs were reported when the surgical intervention was evaluated by the EQ-5D 
than when evaluated by the SF-6D. EQ-5D and SF-6D are the most widely used utility 
measures and were therefore chosen for this study. Due to feasibility reasons, additional 
utility measures, e.g. 15-dimentional (15D) (145) and Health Utility Index (HUI) (146) were 
not included, since this would have increased the burden for the patients.
5.1.3.2 Cost analyses 
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Economists are interested in quantifying the effects of health care interventions for different 
diseases; as such indexes may facilitate comparison of cost and benefit for different 
interventions. The QALYs are frequently used for this purpose, and may act as an important 
factor in the decision and priorities between different health care procedures 
(109;113;114;147). Utilities are transformed to QALYs as the common “metric” for outcomes 
and necessary for a cost-utility analysis. 
The utility scores are generic and thereby eligible for use in different studies and diseases. 
However, the costs included for services or interventions may differ between studies. E.g. 
some studies include only direct costs or the actual cost for a specific treatment and some 
studies also include indirect costs (e.g. economics concerning lost work ability). To make 
QALY analyses comparable, the costs included must be defined precisely, so that the results 
can be interpreted correctly  (117). The cost analyses in Paper IV were based on several 
assumptions which are important for the interpretation of the results: The costs calculated for 
each patient were the costs for the first year after surgery, which were defined as all hospital 
related costs including preoperative examinations, stay in the hospital and all postoperative 
follow-up visits. We assumed that the costs in the second and subsequent years after surgery 
would not be influenced by the surgical intervention, and no medical or other costs were 
included beyond the first year. However, the consequence in terms of over- or 
underestimation of the cost-effectiveness ratio is difficult to assess.
Costs were measured in 2005 and 2006 Norwegian Kroner (NOK) and adjusted to 2008 level 
by means of the consumer price index. The exchange rate used was €1.00~NOK 8.92 (xe.com 
2009.05.26).
We also adopted an economic model suggested by Faulkner et al (118). This model was in 
addition modified by three relevant factors: 
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 the outpatient costs of the surgical intervention;  
 the possibility of re-revisions
 adjustments for the difference in mortality rates in RA compared to the general 
population.
The additional factors were taken into account to make the model more accurate and better 
adapted for the relevant patient group. We started by establishing a deterministic model based 
on the average costs and utilities in the different types of replacement and non-replacement 
surgery. Secondly, a probabilistic model was built, based on the same underlying data, but 
with the uncertainties of the parameters included. Additionally, the overall uncertainty of the 
model was assessed.
Another important assumption that was made before estimating the cost per QALYs was the 
duration of the effect after the surgical interventions. The Norwegian Arthroplasty register 
provides data on revision rates for the replacement surgery depending on type of surgery and 
varied from 0.5% to 2.8% pr. year, depending on the type of surgery (4). Earlier studies report 
that  postoperative changes in outcome measures last for 10 years for replacement surgery 
(4;148-150). Based on this, we assumed a 5 and 10 years risk for revision of arthroplasties in 
our analyses (4).
We assumed no gain in HRQoL during the first year following revision surgery and the 
revision costs were estimated by use of the Norwegian Diagnoses Related Groups (DRG) cost 
weights. The cost of revisions for hip-, knee and ankle arthroplasties were about 20% higher 
than for primary surgery (data from the KOSPA register at Diakonhjemmet Hospital 
comparing costs for primary and revision replacement surgery). For arthroplasties in the 
upper extremities the cost weights were the same for primary and revision surgery (151). 
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Supported by the literature, a conservative estimation was made for the non-replacement 
surgical procedures, assuming that the postoperative changes in the outcome measures lasted 
for 5 years for non-replacement surgery (6;152). Based on the small sample size and the 
different procedures this may be a bias in Paper III and IV. The persistent effect after the non-
replacement surgical interventions is hard to estimate. In Paper III and IV we focused on the 
non-replacement surgical procedures all together as one group and several different 
procedures were included in this group, and a 5 year effect of the procedures may therefore be 
low for some of the procedures, e.g. arthrodesis which is estimated to last longer. Studies with 
larger groups of patients are needed to differentiate between procedures and increase the 
accuracy of this estimate. 
We modelled all cause mortality by assuming that patients with inflammatory rheumatic 
disease have an increased mortality. On the basis of published studies we assumed that the 
standardized mortality ratio (SMR) was 1.27 (153). Mortality rates for the Norwegian 
population were used to assess the survival rates for males and females separately (154) and 
adjusted for the increased SMR seen in RA (1.27) (153). This increased SMR was used for all 
patients in this study. However, different mortality rates after total replacement surgery have 
been reported (5;155). We used mortality data after surgical interventions which showed an 
mortality rate on 0.18% for hip- and 0.16% for knee arthroplasties (156).
The value of costs and money will change over time.  Therefore costs and QALYs were 
discounted by 4% as recommended for assessing the net present value (NPV) in Norway 
(157).
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A definition of the acceptable costs per gained QALY is needed for interpretation of the 
results. The Norwegian Directorate of Health has indicated that a gained QALY is valued to 
be equivalent to approximately €56,040 (NOK 500,000) and this limit for acceptable costs per 
QALY was used in Paper IV (158).
5.1.4 Data analyses 
The data in all papers were considered as approximately normally distributed and parametric 
statistical methods were used in all analyses. 
One of the main methodological problems in longitudinal studies is attrition, the situation that 
not all subjects have data on all time-points. Patients may miss one or more measurements 
during follow-up or miss the final examination. We do not consider the missing values to 
have a major impact on the results, since the LOCF method was used as a conservative 
method to handle missing values. Imputation of missing data may lead to an underestimation 
of the overall time effect, and possibly influence the results in the direction of 
underestimation of the benefits. This phenomenon is stronger when the percentage of missing 
data is higher (159).
The responsiveness of quality of life measures has received considerable attention in the 
literature. A two time-point (pre-post) study design is usually adopted to evaluate this 
property when a gold standard is not available. Among many indices, Cohen's effect size and 
the standardized response mean (SRM) are usually computed. To interpret the results, 
researchers commonly use the same criterion for both indices, even though they are different 
by definition (160;161).  We also chose to apply the widely accepted criteria for strength of 
effects suggested by Cohen (121).
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In Paper I and III SRMs were computed for all measures. The SRM makes it possible to 
compare the magnitude of change between the different instrument scales, independent of 
scaling properties (121). 
5.2 Results 
5.2.1 Physical function and surgical treatment of the upper and lower limb  
RA is a chronic and potentially progressive disease (162). According to the results in Paper I, 
the overall physical function seemed to deteriorate over time, and this finding is  supported 
also by other studies (29;35;163-165). RA may affect several joints and it is well established 
that the physical disability increases over time due to both inflammation and joint destruction 
(34;48;166). However, data on the progression of the disease in different joint areas are very 
limited. Such data are of interest for evaluation of the relative need for surgical procedures in 
the lower and upper limb, and for the understanding the disease course.
In Paper I, deterioration in physical function over a ten years period was consistent across 
several scales and instruments (SF-36 physical function, AIMS2 physical, mobility, walking 
and bending, hands and fingers, household and MHAQ). A strength of the study was the 
consistent results across several different outcome measures within the same dimension. 
However, the HAQ / MHAQ, AIMS2 and SF-36 are not designed for comparison across 
instruments, only for comparison for different patient groups or within the patient. Thus, as 
described by Cohen, SRMs can be used for comparisons of different instruments with 
different scales and were presented in Paper I and III (121).  
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We adjusted for sex, age, disease duration and relevant surgical interventions performed 
during the 10 year follow up. Several variables may influence the patients’ physical function, 
and perhaps we might have included more items, as for example co-morbidities (167).  
The disease duration was 11.6 years at baseline. Although adjustment for disease duration 
was performed in the analyses, all patients had established disease at baseline which is a 
limiting factor for the interpretation of the results. We do not know if the differences seen 
between lower and upper limb in established diseases also are similar earlier in the disease 
course (168).
The magnitude of deterioration was generally larger for activities related to lower than upper 
limb function. Possible explanations for this may be related to different stress on the joints 
due to weight bearing and that a possibly more active inflammation process leads to more 
joint destruction in the lower compared to the upper limb. However, radiographic data were 
not available to examine this hypothesis. We did not adjust for any pharmacological treatment 
since the main treatment is systemic with apparently similar effect on upper and lower limb. 
However, local pharmacological treatment might influence the result, but this information 
was not available. There are also reasons to believe that the joints that are treated with 
pharmacological injections are more likely to be localized in the lower limbs. Surgical 
interventions may also possibly influence the disease course differently for the upper and 
lower limb regarding pain and functional outcomes.  
In Paper I, differences in disease course for upper and lower limbs were found, despite similar 
number of surgical interventions. However, we found that the disease duration at the time of 
surgery was significantly longer for patients referred for foot surgery compared to those 
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referred for hand surgery, and patients referred for foot surgery were also on more potent 
medication (Paper II). Previous studies have indicated that the foot is involved at the disease 
onset to at least the same degree as the hand (169). Studies by Anderson (1996) and Da Silva 
et al. (2003) claim that surgical intervention can be regarded as an outcome measure in the 
treatment of patients with inflammatory arthropathies (79;170). Large joint replacement is 
almost exclusively performed in cases of severe joint damage. According to these previous 
studies, surgery later in the disease course could indirectly pretend a milder disease in the feet 
compared to the hands. In contrast to this suggestion, we found that patients undergoing 
surgical interventions in the feet were on more potent medication at the time of surgery than 
patients undergoing hand procedures, thus indicating that patients with foot surgery were 
more severely affected by their disease (Paper II).  
A possible explanation for the differences in the timing of the surgical treatment for hand and 
feet may be that impaired foot function affects patients to a lesser degree than impaired hand 
function. Other explanations may be that foot surgery has a lower priority than hand surgery, 
both from the surgeons’ and from the rheumatologists’ perspective. The current diagnostic 
criteria system for RA, The ACR 1987 revised criteria for the classification of RA (Table 1), 
seem to support this suggestion, since different focus on hand and foot involvement is 
apparent also in these criteria (41;171;172). Similar, the abbreviated joint counts with 
assessment of 28 joints included in the most widely used disease activity measure (DAS 28) is 
an illustrative example, as  the joints of the foot are not included in this  index (173).
Both Papers I and II focused on possible differences in disease course and timing of surgical 
treatment between the lower and upper limb in patients with inflammatory arthropathies. The 
findings indicated that the impact of foot affliction may be underestimated and that an 
enhanced focus is needed according to timing and planning of surgical interventions for 
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patients with multiple joint destructions. If surgery is postponed beyond a critical point, the 
post-operative benefits may be reduced and complication rate may be higher due to more 
extensive surgical procedures (5;174;175).
5.2.2 Patient-reported- and cost-effectiveness outcomes after surgical intervention   
Significant improvement was seen for most of the health dimensions after surgical 
intervention in patients with inflammatory arthropathies, but the magnitude of improvement 
(as measured by SRMs) differed considerably. The largest improvement was observed for 
pain in the specific joint exposed to surgery, but improvement was seen also for general pain, 
physical function, mental health, vitality and social function (Paper III). Pain is reported to be 
the area of health where most patients would like to see improvement (7) and the level of pain 
is associated with most other self-reported health status measures (95;176). Britton et al 
showed that pain was the most informative outcome measure as predictor of revision and 
correlated well with the patients’ opinion (5;177). Patients referred for surgical interventions 
have expectations about improvement both concerning pain and physical function and our 
findings indicate that patients should be informed that the largest improvement can be 
expected in the area of pain. The expectations about the results of surgery might differ 
between the physician and patient, and  patients expectations might differ according to their 
disease duration and adaptation to their condition (178-180). 
For ethical and practical reasons we were unable to perform an RCT. Thus the efficacy of 
surgery could not be directly compared to a control group. However, in order to enhance the 
interpretation of the data, we took the opportunity to compare patients with replacement vs. 
non-replacement surgery and patients with procedures in the upper and lower limb. 
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Replacement surgery was performed in more than 25 % of the patients (Paper III and IV), 
which is in accordance with previous studies (181;182). Compared to the patients who 
underwent non-replacement surgery, the replacement surgery group reported more pain and 
also worse health across several other dimensions of health preoperatively. Earlier studies 
have shown that preoperative factors with increased pain and reduced physical function 
predict the functional outcome after surgical intervention. These studies indicate that patients 
with severe preoperative status also gain less health compared to patients who have a better 
preoperative status (174;175;183). In contrast to this, we found that patients who underwent 
replacement surgery reported larger improvement in PROMs than the non-replacement group, 
even if the preoperative status was worse. 
We found that the improvement course was similar in patients with replacement and non-
replacement procedures and that the main improvement was observed during the first three 
months postoperatively (Paper III and IV), which is in accordance with previous studies 
reporting early improvement after replacement surgery (184;185). This may indicate  
beneficial results, since a study of Brander et al. indicate that improvement predicts 
subsequent improvement in 5 years after surgery (174).
Many patients will, during their disease course be in need of multiple surgical interventions. 
Thus, a comprehensive treatment plan should be established together with the patient, 
considering the general disease condition, order of surgical interventions for involved joints, 
medical treatment and patients’ preferences and priorities.   
Pain relief and functional improvement are widely accepted treatment goals of surgical 
interventions, and patient-reported outcome measures are pivotal when evaluating results after 
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treatment (112). The combination of a disease-specific scoring system and a quality-of-life 
survey allow a more global assessment, and when evaluating surgical interventions it is 
necessary not only to analyse the benefit of the intervention, but also to ascertain the patients 
satisfaction (5;186).
Arthropathies entail considerable costs to patients in terms of pain and suffering and to 
society in terms of health care resources. The health care costs of RA are reported to be 
comparable to those of coronary artery disease (187;188). An additional challenge in the 
evaluation of specific surgical procedures in rheumatic diseases, is the progressive and 
fluctuating disease course (5), which complicates both the performance and interpretation of 
results of surgical interventions.
When evaluating surgical interventions in patients with inflammatory arthropathies also cost 
analyses are important (5). The real cost of any medical intervention is the health benefits by 
the best use of the resources, and  the objective of economic evaluation is to scrutinize 
alternative use of health resources (189;190).  Surgical interventions in patients with 
inflammatory arthropathies were found to be cost effective when measured with the utility 
score EQ-5D and mainly also when measured by SF-6D (Paper IV).  
The replacement surgical treatment cost more than the non-replacement surgical procedures, 
but these procedures were more cost-effective than non-replacement surgery (Paper IV). The 
first-year costs were somewhat greater for patients who underwent replacement surgery than 
non-replacement procedures, but the gain in utility was larger, so the replacement surgery 
turned out to be most cost-effective.  Total hip replacement (THA) seems to be the most cost 
effective procedure (The cost per gained QALY assessed by EQ-5D ranged from € 5,000 for 
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THA to € 17,800 for non-replacement surgery) as also observed in earlier studies (148). 
Previous studies indicate that total hip replacement surgery in patients with osteoarthritis and 
inflammatory arthropathies is more cost-effective than coronary artery bypass grafting and 
kidney transplantation (5;190). However, the cost outcomes reported in Paper IV were based 
on relative small sample sizes and this may limit the interpretation of the results. 
The category non-replacement interventions in this study included many different types of 
surgical procedures. Uncertainty of the results due to the relative small sample sizes for the 
various non-replacement surgical procedures is a limitation and more research in larger study 
populations are needed to distinguish between cost outcomes for the different non-
replacement surgical procedures. On the other hand, the positive effects of several of these 
procedures are expected to last longer than the 5 years used as a presumption in the 
calculation of costs in this study. 
Although the costs from the surgical procedures, including the materials, were larger for 
replacement surgery than non-replacement surgery, time of stay in hospital was the single 
factor that most strongly inflated the total costs, independent of type of surgical procedure. 
Costs related to stay in hospital constituted nearly half of the total costs the first year. An 
implication of this finding is that the costs after surgical procedures have the potential to be 
decreased by reducing the length of stay in hospital. An earlier study has shown that reduction 
in the length of stay in hospital provide savings in the total costs without adversely affecting 
the overall outcome (25).   
The cost-effectiveness analyses in Paper IV have some limitations. For example, the influence 
of medical costs and patients' ability to work were not considered. Cost-outcome descriptions 
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are important in modern medicine, as priorities have to be made between increasing numbers 
of costly therapeutic opportunities. Yet, it is important to be aware that QALYs are a 
simplified and theoretical way of describing health status, and changes in some health status 
dimensions might therefore not be captured by this approach.
A cost-effective use of resources implies that the treatment which gives the highest expected 
health gain per unit of cost should be prioritized (191). The use of expensive biological 
medical treatment in RA and related diseases has increased tremendously during the last years 
and has been shown to be effective, but not without side-effects (192-197).  Systemic 
pharmacological treatment is considered the main and first-line treatment of rheumatic 
diseases. However, despite the fact that some recent  studies have demonstrated a decline in 
orthopaedic surgery in patients with inflammatory arthropathies (9;13;170), and the fact that 
surgical interventions may have adverse effects (194), it is still important to consider surgery 
as a beneficial supplement or alternative treatment for patients with inflammatory 
arthropathies.  
6. Conclusions 
The overall physical function measured by the AIMS2 physical and the MHAQ deteriorated 
over a 10-year period in patients with established RA, and the lower limb function 
deteriorated significantly more than upper limb function.  
Significant differences in disease characteristics were found for patients referred for hand and 
foot surgery. Patients undergoing surgical procedures in the foot had significantly longer 
disease duration and were more frequent on potent medication at the time of surgery 
compared to patients undergoing hand surgery. 
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We found that pain, physical function and health related quality of life improved significantly 
after surgical interventions in patients with inflammatory arthropathies, with the largest 
improvement in pain scores.  
Patients referred for replacement surgery reported more pain, lower physical function and 
health related quality of life than patients referred for non-replacement surgical interventions 
preoperatively. However, improvements after surgery were larger for the replacement group 
compared to the non-replacement group. The results for upper and lower limb surgery were 
similar for all outcomes. 
Elective orthopaedic surgery in patients with inflammatory arthropathies was cost-effective 
when measured with the EQ-5D, and some procedures were also cost-effective estimated with 
the SF-6D.  Replacement surgery was more expensive procedures than non-replacement 
surgical interventions. Yet, replacement surgery was more cost effective, since then gains in 
QALYs were larger after replacement than after non-replacement surgery. Hip replacement 
surgery was most cost-effective, irrespective of analysis method. 
7. Clinical implications 
This thesis provides relevant data concerning the progress of physical function in patients 
with inflammatory arthropathies. Despite a more severe disease progression in the lower 
compared to the upper limb, the lower limb seem to be treated later in the disease course. This 
observation might indicate that the disease severity in the lower limb is underestimated and 
that treatment procedures are initiated later than for the upper limb.  
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A treatment plan based on clinical decisions and patients’ priorities is important to ensure 
adequate treatment at the right time for joints involved. Later treatment than necessary might 
indicate reduced treatment options for the patients.  
This thesis also provides important data concerning patient-reported outcomes after surgical 
interventions. The data are relevant for the results to be expected from surgical procedures, 
and, according to this, patients' should be informed that largest improvement can be expected 
in pain scores.
Further, the cost benefit after surgical interventions is of importance for patient, physician, 
and society. Importantly we showed that the most expensive type of interventions 
(replacement surgery) also was the most cost-effective, and that surgical interventions, and 
especially replacement surgery, represent an important cost-effective treatment alternative for 
patients with painful, destructed joints. 
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ABSTRACT
Objective: To examine the effectiveness of orthopaedic
surgery in patients with inflammatory arthropathies with
regard to longitudinal changes in pain, physical function
and health-related quality of life and explore differences in
effectiveness between replacement versus non-replace-
ment surgery and surgery in the upper versus the lower
limb.
Methods: 255 patients (mean age 57.5 years (SD 13.1),
76.7% female) with inflammatory arthropathies under-
went orthopaedic surgical treatment and responded to
mail surveys at baseline and during follow-up (3, 6, 9 and
12 months). The booklet of questionnaires included the
arthritis impact measurement scales 2 (AIMS2), health
assessment questionnaire (HAQ), short form 36 (SF-36),
EQ-5D and visual analogue scales (VAS) addressing
patient global, fatigue, general pain and pain in the actual
joint. Standardised response means (SRM) were calcu-
lated to estimate the magnitude of improvement.
Results: Significant improvement was seen for most of
the dimensions of health, the largest improvement for
pain in the actual joint (SRM 1.17) at one year follow-up.
SRM for AIMS-2 physical, SF-36 physical and HAQ were
0.1, 0.48 and 0.05, respectively. The overall numeric
improvement (SRM) in utility was 0.10 (0.37) with EQ-5D
and 0.03 (0.27) with SF-6D. Improvement overall was
similar after surgery in the upper versus the lower limb,
but was larger in patients undergoing replacement
surgery than in patients undergoing other surgical
procedures (SRM 1.54 vs 1.08 for pain in the actual joint).
Conclusions: Surgical procedures have a major positive
impact on pain in the actual joint, but improvement is less
in other dimensions of health. Health benefits were larger
after replacement surgery than after other surgical
procedures.
Joint destruction is one of the most serious
consequences of inflammatory arthropathies. The
overall treatment goal for these patients with
established disease is to reduce pain, minimise loss
of function and preserve health-related quality of
life (HRQoL). Signs and symptoms of inflamma-
tory arthropathies have been proved to be reduced
with drug treatment, but still many patients need
surgical intervention,1 2 even if the level of health
status in patients with rheumatoid arthritis (RA)
has improved over the past years.3
Orthopaedic surgery may be expected to provide
pain relief and preserve and even improve function
in patients with inflammatory arthropathies.
Patient-oriented evaluations of pain, function and
HRQoL are of importance when evaluating
whether treatment goals have been achieved by
surgical interventions.4 Patient-reported outcome
(PRO) measures provide opportunities to address
dimensions of health that are of relevance to the
patient and are shown to be as reliable and
responsive as physician measures and congruent
with measures of inflammation.5 6
Randomised controlled trials (RCT) or compara-
tive observational studies examining the effects of
surgical interventions for patients with rheumatic
diseases are lacking.7 However, even if RCT are
associated with the highest level of evidence,
longitudinal observational studies can also provide
important evidence on effectiveness because the
patient population is unselected and the follow-up
is performed in a real-life setting.8 9 The objective
of this study was to examine the effectiveness of
orthopaedic surgery in patients with inflammatory
arthropathies with regard to longitudinal changes
in pain, physical function and HRQoL. We
especially focused on comparisons between repla-
cement and non-replacement surgery and between
surgery performed in the upper and lower limbs.
MATERIALS AND METHODS
Patients
This study included 255 patients with inflamma-
tory arthropathies and inclusion occurred during
the period February 2005 to May 2006 at
Diakonhjemmet Hospital, Oslo, Norway. The 255
patients underwent orthopaedic surgical treatment
and responded to the mail surveys at baseline and
at least one point of follow-up. Patients with the
diagnosis of osteoarthritis were not included and
we also excluded patients who underwent revision
surgery, surgery because of fractures or secondary
infections. Each patient was only included once
(first intervention during the inclusion period).
The distribution of diagnoses was as follows: RA
(64.2%), juvenile RA (3.9%), ankylosing spondylitis
(5.1%), psoriatic arthritis (7.4%) and other arthri-
tides (12.0%). The mean baseline age was
57.5 years (SD 13.1) and 76.7% were women.
Patients with RA underwent more replacement
surgery than patients with other arthritides (30.4%
vs 17.8%). The distribution of surgical procedures
in the upper and lower limb was similar in RA and
the other arthritides.
Age and gender were similar in the groups of
patients who underwent surgery in the upper
and lower limb. The patients who underwent
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replacement surgery were older (61.4 vs 56.0 years, p=0.006)
than patients who underwent other surgical interventions, but
the sex ratio was similar. All patients were seen by a
physiotherapist as part of the routine and, if needed, they were
offered physiotherapy after the surgical procedure.
Data collection
The PRO were recorded at hospital admission and then by mail
surveys 3, 6, 9 and 12 months after the surgical procedure. The
booklet of questionnaires included both generic and disease-
specific health status measures (arthritis impact measurement
scales 2 (AIMS2), the health assessment questionnaire (HAQ),
the short form 36 (SF-36), the utility instrument EQ-5D and
four visual analogue scales (VAS), which addressed patient
global assessment of disease, fatigue, general pain and pain in
the specific joint undergoing surgery.
Instruments
AIMS2 is a multidimensional disease-specific measure that has
been translated into many languages including Norwegian.10 11
The first 57 items of AIMS2 are broken into 12 scales: mobility
(five items); walking and bending (five items); hand and finger
function (five items); arm function (five items); self-care tasks
(four items); household tasks (four items); social activity (five
items); support from family and friends (five items); arthritis
pain (five items); work (four items); level of tension (five items)
and mood (five items). The scales may be combined into a five-
component model reflecting the physical dimension, affect,
symptoms, social interaction and role. The score of each scale
ranges from 0 to 10 (10 represents worst health). AIMS2 was
scored according to the AIMS2 users’ guide issued by the Boston
University Arthritis Centre.
The HAQ is a disease-specific measure for RA and asks
questions about the patient’s ability to perform activities of
daily living.12 The HAQ includes questions assessing difficulty
over the past week in 20 specific functions, grouped into eight
categories: dressing and grooming; arising; eating; walking;
personal hygiene; reaching; gripping and other activities. The
responses to ‘‘are you able to do…’’ were scored 0–3 (without
any difficulty = 0, unable to do = 3). The total HAQ score is
the mean of the scores for the eight categories. Scores were
adjusted for the use of assistive devices.
The SF-36 is a generic health status measure and has been
used in a variety of conditions including RA, musculoskeletal
disorders and patients who have undergone replacement
surgery.13–15 The eight multi-item scales are as follows: physical
functioning (10 items); role limitations due to physical health
(four items); bodily pain (two items); general health (five
items); vitality/energy/fatigue (four items); social functioning
(two items); role limitations due to emotional problems (three
items) and mental health (five items). SF-36 scales were scored
according to published scoring procedures, each expressed with
values from 0 to 100 (0 = poor health).
SF-6D is a utility score which is derived from the SF-36. The
eight dimensions in SF-36 are reduced to six in SF-6D. The level
of severity in each dimension is determined by responses to
related items in SF-36. The six dimensions are: physical
function; role limitations; social function; pain; mental health
and vitality.16 The utility score has a range from 0 to 1, but the
lowest achievable value with SF-6D for living patients is 0.29.17
The EQ-5D is a standardised utility instrument with a three-
level five-dimensional format.18 19 The EQ-5D includes the
following dimensions: mobility; self care; usual activities;
pain/discomfort and anxiety/depression. Negative values can
also be achieved in living patients.17
Surgical procedures
The different types of surgical procedures are listed in appendix
1 (published online only as a supplementary file). The surgical
procedures were categorised into replacement surgery and non-
replacement surgery, and also into surgical procedures per-
formed in upper versus lower limbs. The primary large joint
replacement arthroplastics are referred to as replacement
surgery in this article. For analytical purposes total replacements
in the small joints (metacarpophalangeal, proximal inter-
phalangeal and metatarsophalangeal) were categorised together
with other surgical procedures than replacement surgery in the
larger joints in order to be able to analyse homogenous groups
according to the postoperative follow-up and rehabilitation.
Statistical analyses
Changes within patient groups during follow-up from baseline
to 12 months were examined by paired sample t test. The
standardised response mean (SRM) reflects the magnitude of an
improvement (or deterioration) and was computed as the
change from baseline to the 12-month follow-up divided by the
standard deviation of the change score. The magnitude of
the SRM was interpreted in terms of the thresholds introduced
by Cohen20 for effect sizes: ‘‘trivial’’ (,0.20), ‘‘small’’
(.0.20,0.50), ‘‘moderate’’ (.0.50,0.80) or ‘‘large’’ (.0.80).
The SRM is comparable across the different instruments,
independent of the instrument scales.
An independent sample t test was used to compare long-
itudinal changes between groups (replacement vs non-replace-
ment surgery and surgery in upper vs lower limb). The last
observation carried forward (LOCF) was used to replace missing
values during follow-up. p Values equal to or below 0.05 were
considered to be statistically significant. Correction for the
number of tests was not performed as this was an explorative
study. SPSS 14.0 and SPSS 15.0 were used in the analyses.
RESULTS
Surgical procedures in upper versus lower limbs were performed
in 42.4% and 57.6% of the 255 patients. Replacement surgery
was performed in 25.6% of the patients and 75.0% of these
procedures were performed in the lower limbs.
Significant improvement was seen for most of the dimensions
of health (fig 1), but the magnitude of improvement differed
considerably. Not surprisingly, the largest improvement was
observed for pain reported from the specific joint exposed to
surgery (SRM 1.17), but other pain measures also improved
(SRM pain VAS 0.43, AIMS2 pain 0.52, SF-36 bodily pain 0.47;
fig 1).
The improvement for physical functioning differed between
instruments. The SRM for SF-36 physical was 0.48, but only
0.05 for HAQ and 0.10 for AIMS2 physical. Other dimensions of
health also improved, but with small effect sizes, eg, fatigue
VAS (0.23) and the SF-36 mental (0.22), vitality (0.24) and social
function (0.16) (fig 1).
The pattern of improvement was similar overall after surgical
procedures in the lower and upper limb, but changes were, as
expected, different for measures that specifically addressed
functional aspects in the lower (eg, SF-36 physical, AIMS2
mobility, AIMS2 walking and bending) versus the upper (eg,
AIMS2 arms) limbs (table 1).
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A larger improvement across all dimensions of health was
observed after replacement surgery compared with non-replace-
ment surgery (table 2).
The overall improvement (change) in utility was 0.10 (SRM
0.37) with EQ-5D and 0.03 (SRM 0.27) with SF-6D. Figure 2
illustrates that this improvement was generally captured within
6 months. The other HRQoL instruments showed the same
pattern of response as SF-6D and EQ-5D. A large improvement
was observed after 3 months and stabilised thereafter.
The gained HRQoL expressed in utilities was larger after
replacement surgery than after non-replacement surgery (table 2).
DISCUSSION
Pain is the area of health in which most patients with RA would
like to see an improvement.21 The current study demonstrates
that a major improvement is observed in patient-reported pain
after orthopaedic surgical procedures in patients with inflam-
matory arthropathies (fig 1). This finding was consistent for
procedures in the lower and upper limb and for replacement and
non-replacement surgery (tables 1 and 2).
Improvement in the measures of physical functioning was
generally smaller than in measures of pain (fig 1). This
observation supports the theory that pain in the actual joint
Figure 1 Magnitude of improvement
displayed as standardised response mean
across a variety of measures of pain,
function and health-related quality of life.
*p(0.05, **p(0.01, ***p(0.001
(paired t test for the mean change).
AIMS2, arthritis impact measurement
scales 2; HAQ, health assessment
questionnaire; SF-36, short form 36, BP,
bodily pain; GH, general health; MH,
mental health; PF, physical function; SF,
social function; VT, vitality; VAS, visual
analogue scale.
Table 1 Mean baseline values for measures of pain, function and HRQoL, change and SRM from baseline to
12 months and the mean difference between the changes in patients with surgical procedures in the upper
versus lower limbs
Upper limb Lower limb Between-
group
p ValueBaseline Change SRM Baseline Change SRM difference
HAQ (0–3) 0.71 0.035 0.12 0.66 0.00 0.01 0.00 0.96
SF-36 (0–100)
Mental health 75.45 2.68 0.20 72.20 3.08** 0.24 0.39 0.83
Vitality 43.13 4.32* 0.23 42.65 4.29** 0.25 0.03 0.99
Bodily pain 33.66 7.96*** 0.45 35.22 10.03*** 0.49 2.07 0.44
General health 48.04 0.41 0.03 46.06 3.73** 0.26 3.32 0.11
Social function 68.98 1.56 0.07 64.29 5.88* 0.23 4.32 0.20
Physical function 49.75 2.89** 0.21 38.20 12.88*** 0.69 9.98 0.00
VAS (0–100)
General pain 53.00 12.12*** 0.47 47.84 9.86*** 0.40 2.26 0.51
Pain in operated joint 58.49 33.56*** 1.12 60.50 35.67*** 1.22 2.11 0.61
Fatigue 46.61 7.05* 0.26 46.14 5.18*** 0.20 1.87 0.60
Patient global 54.31 11.06*** 0.46 53.15 11.35*** 0.44 0.29 0.93
AIMS2 (0–10)
Mobility 1.60 0.22 0.14 2.01 0.18 0.13 0.39 0.06
Walking and bending 4.58 0.01 0.00 5.74 0.88*** 0.37 0.89 0.01
Hand and fingers 3.41 0.27 0.13 2.56 0.08 0.06 0.19 0.42
Arms 2.21 0.28 0.17 1.27 0.14 0.12 0.42 0.03
Household 1.63 0.24 0.15 1.59 0.02 0.01 0.22 0.27
Self-care 0.65 0.16 0.11 0.55 0.07 0.07 0.23 0.18
Pain 6.49 1.16*** 0.55 5.90 1.04*** 0.50 0.12 0.68
Physical 2.36 0.01 0.01 2.30 0.17* 0.21 0.18 0.14
SF6D (0–1) 0.60 0.02 0.16 0.59 0.04*** 0.35 0.02 0.18
EQ5D (0–1) 0.47 0.06* 0.23 0.45 0.13*** 0.48 0.67 0.08
*p,0.05; **p,0.01; ***p,0.001. p Values for within-group changes were based on a paired sample t test, p values for between-
groups differences were based on an independent sample t test.
AIMS2, arthritis impact measurement scales 2; HAQ, health assessment questionnaire; HRQoL, health-related quality of life; SF-36,
short form 36; SRM, standardised response mean; VAS, visual analogue scale.
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is probably the most important indicator of treatment benefit
and this observation is of relevance when informing the patients
preoperatively about their treatment expectations.
We also observed an improvement in other dimensions of
health that are important to patients but not considered as
directly related to benefit from surgery. For example, both
fatigue and SF-36 vitality, as well as SF-36 mental and social
functioning improved more than some of the scales reflecting
physical functioning, even if the effect sizes were small or trivial
(fig 1). It is known that the level of pain is strongly related to
most other self-reported health status measures.22 23 The
observed improvements in measures of fatigue, mental and
social functioning may thus also reflect reductions in pain
intensity. Furthermore, pain has a major impact on the patient
global assessment of the disease and we assume that the
improvement in global VAS is caused by an improvement in
pain.22 This assumption is also supported by a strong correlation
between changes in these two dimensions in the current study
(r = 0.64, p,0.01).
A limitation of this study was the lack of other disease
activity measures, including joint counts and acute phase
reactants. However, inflammatory activity is strongly related
both to physical functioning and pain,23 24 and the apparent
differences in the magnitude of improvement between these
dimensions do not support the belief that the inflammatory
activity was considerably changed during follow-up. The rate of
non-respondents was similar to the observed rates in mail
surveys in the Oslo RA register.25 Patients who underwent
replacement surgery had a few percentages more missing values
than patients who underwent non-replacement surgery and the
oldest patients also had a slightly higher percentage of missing
values than younger patients. The missing values were
independent of gender and diagnosis. We do not consider the
missing values to have any major impact on the results because
LOCF was used as a conservative method to handle missing
values. A possible influence on the results was probably in the
direction of an underestimation of the benefit.
Cost-effectiveness analyses are important in modern medicine
as priorities have to be determined between an increasing
number of costly therapeutic opportunities. The different
magnitude of improvement with EQ-5D and SF-6D was as
expected based on the different profiles of these instruments
with regard to ceiling and floor effects.17 26
We have previously shown that lower limb function
deteriorates more than upper limb function over a 10-year
period in patients with RA.27 Therefore, we wanted to compare
the outcomes of upper and lower extremity surgery. Many of
the replacement surgical procedures in the lower limb are also
performed in patients with osteoarthritis.
Replacement surgery was performed in 25.6% of patients, and
this frequency is in accordance with previous studies.28 29
Compared with patients who underwent non-replacement
surgery, the replacement surgery group reported worse health
preoperatively, and a larger improvement was observed during
follow-up, although both groups had a significant improvement
in most scores (table 2). This preoperative difference in HRQoL
between the patients who underwent replacement surgery
versus non-replacement surgery may be a bias in the study.
Table 2 Mean baseline values for measures of pain, function and HRQoL, change and SRM from baseline to
12 months and the mean difference between the changes in patients with replacement surgery versus other
procedures
Replacement surgery Non-replacement surgery Between-
group
p valueBaseline Change SRM Baseline Change SRM difference
HAQ (0–3) 0.80 0.04 0.09 0.62 0.01 0.03 0.03 0.62
SF-36 (0–100)
Mental health 72.64 5.59** 0.45 73.25 1.78 0.13 3.74 0.08
Vitality 42.97 5.39* 0.30 43.00 3.90* 0.22 1.42 0.62
Bodily pain 30.89 14.68*** 0.70 35.20 7.53*** 0.42 6.46 0.03
General health 47.04 3.41** 0.26 46.82 1.87 0.12 0.98 0.68
Social function 61.33 5.39*** 0.36 67.90 2.02 0.09 7.11 0.06
Physical function 32.04 17.27*** 0.78 47.19 5.52*** 0.39 12.12 0.00
VAS (0–100)
General pain 53.94 19.42*** 0.76 49.19 7.70*** 0.32 11.09 0.01
Pain in operated joint 66.17 49.17*** 1.54 58.40 28.93*** 1.08 20.64 0.00
Fatigue 47.77 11.10** 0.41 46.47 4.77* 0.19 5.51 0.19
Disease activity 59.11 19.84*** 0.73 52.37 8.79*** 0.38 10.62 0.01
AIMS2 (0–10)
Mobility 2.05 0.11 0.06 1.75 0.02 0.02 0.19 0.42
Walking and bending 6.25 1.30** 0.45 4.95 0.20 0.10 1.10 0.00
Hands and fingers 2.63 0.08 0.06 2.85 0.22 0.12 0.08 0.77
Arms 2.06 0.32 0.24 1.57 0.03 0.02 0.34 0.16
Household 2.01 0.01 0.01 1.42 0.17 0.13 0.13 0.58
Self-care 0.87 0.01 0.01 0.54 0.03 0.04 0.03 0.89
Pain 5.91 1.45*** 0.66 6.27 0.97*** 0.47 0.43 0.21
Physical 2.68 0.25 0.23 2.18 0.04 0.05 0.21 0.15
SF6D (0–1) 0.57 0.06*** 0.54 0.60 0.02* 0.18 0.03 0.04
EQ5D (0–1) 0.39 0.22*** 0.76 0.48 0.06* 0.24 0.15 0.00
*p,0.05; **p,0.01; ***p,0.001. p Values for within-group changes were based on a paired sample t test, p values for between-
group differences were based on an independent sample t test.
AIMS2, arthritis impact measurement scales 2; HAQ, health assessment questionnaire; HRQoL, health-related quality of life; SF-36,
short form 36; SRM, standardised response mean; VAS, visual analogue scale.
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Importantly, the mean change in EQ-5D utility was 0.22 in the
replacement surgery group and only 0.06 in the non-replacement
group. Replacement surgery is more expensive than other
procedures, and a larger benefit should therefore also be expected
for such procedures, if they can be considered cost-effective. Some
studies have shown declining use of orthopaedic surgery in
patients with RA inflammatory arthropathies,30–32 but also that
disability and other HRQoL scores predicted subsequent prosthe-
sis surgery in a cohort of early RA patients.33
Self-administered questionnaires were used for the assess-
ment of all outcomes in the current study. PRO have been
shown to provide information similar to many clinical measures
and are at least as responsive.6 Furthermore, self-reported
questionnaires appear to be a cost-effective and attractive
approach for quantitative assessment and monitoring of health
status of the individual patient.34 A strength of this study was
the use of several instruments capturing the same construct or
domain.17 Consistent results across instruments support the
robustness of the results. An exception was the results achieved
with the instruments measuring physical function, but the scale
from SF-36 has a stronger focus on lower limbs than AIMS2
physical and HAQ. However, the large number of instruments
represented a burden for the patients as missing values occurred
with a frequency of approximately one third at each point of
follow-up. Therefore, a conservative analytical approach
(LOCF) was used to replace missing values.
Surgical interventions are complicated procedures that can
have major and fatal consequences for the patient. The outcome
not only depends on the operative technique, the proper
selection of the type of surgery and postoperative rehabilitation,
but also on the progression of the disease and the state of
advancement of pathological changes in other joints. Further
research is needed to evaluate the costs and consequences of
surgical procedures that are offered to patients with inflamma-
tory arthropathies. RCT are needed, but are difficult to perform.
The current observational study showed that surgical
procedures had a major positive impact on pain, but the overall
improvement on physical functioning was of similar magnitude
as the improvement in psychosocial variables and fatigue. These
observations support the belief that pain rather than function
should be the major indication for surgical procedures and
contributes to the understanding of how patients should be
informed about their expectations of surgical procedures.
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